Castle biosciences stock.

Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...Dec 4, 2023 · Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ... Castle Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CSTL updated stock price target summary.2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)... Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and ...

Dec 1, 2023 · In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.35 beat Celcuity's score of -0.30 indicating that Celcuity is being referred to more favorably in the media. 2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)...Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.

Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersCastle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ...

Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 -4.19% -0.60 Home CSTL •... FRIENDSWOOD, Texas, November 08, 2023--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major …Dec 1, 2023 · In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Castle Biosciences and 3 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.35 beat Celcuity's score of -0.30 indicating that Celcuity is being referred to more favorably in the media. Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ...

Castle Biosciences. Manufacturing · Texas, United States · 342 Employees. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Castle Biosciences is headquartered in Friendswood, Texas with operations in Phoenix, Arizona. Read More. View Company Info for Free

The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...Castle Biosciences price target raised to $30 from $25 at Baird 07/25/23 Craig-Hallum Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal 07/07/23 KeyBanc Castle Biosciences stock up amid ADLT status for DecisionDx-SCC, says KeyBanc 07/07/23 Lake Street Lake Street says Castle …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...

4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.November 22, 2023 at 3:28 AM · 2 min read. Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares ...Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …FRIENDSWOOD - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx-Melanoma and DecisionDx-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6.A high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences stock trading at $18.06 per share, the total value of Castle Biosciences stock (market capitalization) is $486.00M. Castle Biosciences stock was originally listed at a price of …Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Which Castle Biosciences insiders have been selling company stock? The following insiders have sold CSTL shares in the last 24 months: Daniel Bradbury ($6,274,776.69), and Derek J Maetzold ($1,265,588.97).

Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences ( CSTL – Research Report ), with a price target of $43.00. The company’s shares closed ...Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ...Nov 24, 2023Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...Europe PMC is an archive of life sciences journal literature.According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Track Castle Biosciences Inc (CSTL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.

Nov 24, 2023Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,642 on 14 July 2023.. The largest trade Kim's ever made was exercising 3,825 units of Castle Biosciences …Tobin Juvenal CSTL stock SEC Form 4 insiders trading. Tobin has made over 5 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Tobin exercised 6,173 units of CSTL stock worth $14,753 on 1 March 2023.6,173 units of CSTL stock worth $14,753 on 1 March 2023.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued. The Castle Biosciences stock prediction for 2025 is currently $ 28.00, assuming that Castle Biosciences shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 40.19% increase in the CSTL stock price. Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,653 on 2 June 2023.DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513

Dec 4, 2023 · Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ... Jun 5, 2023 · FRIENDSWOOD - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx-Melanoma and DecisionDx-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6. Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. Of the 172 institutional investors that purchased Castle Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Granahan Investment Management LLC ($1.82M), Principal Financial Group Inc. ($1.13M), Millennium Management LLC ($1.03M), Wasatch Advisors Inc. …Instagram:https://instagram. lidar stock pricesteel pennies 1943 worthbreitsklx energy Cathie Wood's Top 15 Small-Cap Stock Picks Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2022 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ: ...Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. spacex stock price today per shareis everest health insurance good What is the target price for Castle Biosciences (CSTL) stock? The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set ...Biosciences; Research Funding - Castle Biosciences. CPG: Other Remuneration - Indiana University. DM: President and CEO - Castle Biosciences; Stock Ownership - Castle Biosciences. KMO: Director of ... chase refi mortgage rates Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks to Buy Now Castle Biosciences, Inc. (NASDAQ ...The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...